Bank of New York Mellon Corp lowered its holdings in BioNTech SE Sponsored ADR (NASDAQ: BNTX) by 64.6% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 40,483 shares of the company's stock after selling 73,978 shares during the period....

BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript

BioNTech NASDAQ: BNTX reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to...

Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.

Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer , taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types Multiple...

Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (“CEO”), who will take office by February 1,...

BioNTech trades near cash value, implying its advanced oncology pipeline is valued at nearly zero—an opportunity I rate as BUY. BNTX's €16.8B liquidity, $1B buyback, and cost restructuring enable multi-year funding without dilution, reflecting strong management conviction. Key 2026 catalysts...

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable...

BioNTech's oncology pipeline could help it make a dent in this large and growing market. However, there is one thing investors should consider before initiating a position.

MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET...

Baader Bank Aktiengesellschaft lowered its stake in BioNTech SE Sponsored ADR (NASDAQ: BNTX) by 10.4% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 136,425 shares of the company's stock after selling 15,914 shares during the period. BioNTech accounts for...

Amova Asset Management Americas Inc. acquired a new position in shares of BioNTech SE Sponsored ADR (NASDAQ: BNTX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 77,694 shares of the company's stock, valued at...

On July 8, the Ark Genomic Revolution ETF sold roughly $7.4 million worth of BioNTech stock. Cathie Wood's ETF has now almost completely sold its entire position in BioNTech.

They may not remain cheap for too much longer.

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.